Isoxsuprine

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Isoxsuprine
Accession Number
DB08941
Type
Small Molecule
Groups
Approved, Withdrawn
Description

A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.

Structure
Thumb
Synonyms
  • Isoxsuprine
Product Ingredients
IngredientUNIICASInChI Key
Isoxsuprine hydrochlorideV74TEQ36CO579-56-6QVPSGVSNYPRFAS-BQZDIUEZSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isoxsuprine HydrochlorideTablet10 mg/1OralBI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY2011-06-02Not applicableUs
Isoxsuprine HydrochlorideTablet10 mg/1OralBi-Coastal Pharmaceutical Corporation2011-06-02Not applicableUs
Isoxsuprine HydrochlorideTablet20 mg/1OralEci Pharmaceuticals Llc2011-08-23Not applicableUs
Isoxsuprine HydrochlorideTablet20 mg/1OralPhysicians Total Care, Inc.1996-06-122011-06-30Us
Isoxsuprine HydrochlorideTablet10 mg/1OralEci Pharmaceuticals Llc2011-06-02Not applicableUs
Isoxsuprine HydrochlorideTablet20 mg/1OralVista Pharmaceuticals, Inc.1997-09-19Not applicableUs
Isoxsuprine HydrochlorideTablet20 mg/1OralVedco Dba Valdar2011-08-23Not applicableUs
Isoxsuprine HydrochlorideTablet20 mg/1OralBI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY2011-06-02Not applicableUs
Isoxsuprine HydrochlorideTablet20 mg/1OralBi-Coastal Pharmaceutical Corporation2011-06-02Not applicableUs
VasodilanTablet20 mg/1OralBristol Myers Squibb1997-01-012007-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralVista Pharmaceuticals, Inc.1997-09-19Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (10 mg/1)TabletOralBi-Coastal Pharmaceutical Corporation2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralBI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralPhysicians Total Care, Inc.1996-06-122011-06-30Us
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (10 mg/1)TabletOralBI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralEci Pharmaceuticals Llc2011-08-23Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralVedco Dba Valdar2011-08-23Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (10 mg/1)TabletOralEci Pharmaceuticals Llc2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralBi-Coastal Pharmaceutical Corporation2011-06-02Not applicableUs
Categories
UNII
R15UI3245N
CAS number
395-28-8
Weight
Average: 301.386
Monoisotopic: 301.167793605
Chemical Formula
C18H23NO3
InChI Key
BMUKKTUHUDJSNZ-HBUWYVDXSA-N
InChI
InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3/t13-,14-,18-/m1/s1
IUPAC Name
4-[(1S,2R)-1-hydroxy-2-{[(2R)-1-phenoxypropan-2-yl]amino}propyl]phenol
SMILES
C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of hypertension can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Isoxsuprine.
1-benzylimidazoleThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Isoxsuprine.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Isoxsuprine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 3-isobutyl-1-methyl-7H-xanthine.
3,5-diiodothyropropionic acidThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 3,5-diiodothyropropionic acid.
3,5-DiiodotyrosineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 3,5-Diiodotyrosine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Isoxsuprine.
4-MethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Isoxsuprine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of hypertension can be increased when Isoxsuprine is combined with 5-methoxy-N,N-dimethyltryptamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11779629
PubChem Substance
310264908
ChemSpider
9954311
Wikipedia
Isoxsuprine
ATC Codes
C04AA01 — Isoxsuprine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentDisseminated Sclerosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral20 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0507 mg/mLALOGPS
logP2.06ALOGPS
logP2.56ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)9.65ChemAxon
pKa (Strongest Basic)9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area61.72 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity86.64 m3·mol-1ChemAxon
Polarizability34.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Phenoxy compounds / Phenol ethers / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Phenylpropane / Phenol ether / Phenoxy compound / Alkyl aryl ether / Phenol / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Secondary alcohol / 1,2-aminoalcohol / Secondary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on May 26, 2014 15:29 / Updated on December 02, 2019 08:33